Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.

Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM.

JAMA Neurol. 2013 Feb;70(2):201-7. doi: 10.1001/jamaneurol.2013.593.

2.

Gender difference in levels of Cu/Zn superoxide dismutase (SOD1) in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Frutiger K, Lukas TJ, Gorrie G, Ajroud-Driss S, Siddique T.

Amyotroph Lateral Scler. 2008 Jun;9(3):184-7. doi: 10.1080/17482960801984358.

PMID:
18574763
3.

Misfolded superoxide dismutase-1 in CSF from amyotrophic lateral sclerosis patients.

Zetterström P, Andersen PM, Brännström T, Marklund SL.

J Neurochem. 2011 Apr;117(1):91-9. doi: 10.1111/j.1471-4159.2011.07177.x. Epub 2011 Feb 9.

4.

Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.

Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM.

Eur J Neurol. 2007 Dec;14(12):1329-33. Epub 2007 Sep 26.

PMID:
17903209
5.

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME.

Lancet Neurol. 2013 May;12(5):435-42. doi: 10.1016/S1474-4422(13)70061-9. Epub 2013 Mar 29. Erratum in: Lancet Neurol. 2013 May;12(5):423.

6.

Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study.

Lange DJ, Andersen PM, Remanan R, Marklund S, Benjamin D.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):199-204. doi: 10.3109/17482968.2012.724074. Epub 2012 Sep 17.

PMID:
22985433
7.

Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.

Lange DJ, Shahbazi M, Silani V, Ludolph AC, Weishaupt JH, Ajroud-Driss S, Fields KG, Remanan R, Appel SH, Morelli C, Doretti A, Maderna L, Messina S, Weiland U, Marklund SL, Andersen PM.

Ann Neurol. 2017 Jun;81(6):837-848. doi: 10.1002/ana.24950. Epub 2017 Jun 9.

8.

Analysis of smoking and LPO in ALS.

Anand A, Gupta PK, Prabhakar S, Sharma S, Thakur K.

Neurochem Int. 2014 May;71:47-55. doi: 10.1016/j.neuint.2014.04.004. Epub 2014 Apr 12.

PMID:
24726768
9.

Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis.

Turner BJ, Atkin JD, Farg MA, Zang DW, Rembach A, Lopes EC, Patch JD, Hill AF, Cheema SS.

J Neurosci. 2005 Jan 5;25(1):108-17.

11.

Silencing strategies for therapy of SOD1-mediated ALS.

van Zundert B, Brown RH Jr.

Neurosci Lett. 2017 Jan 1;636:32-39. doi: 10.1016/j.neulet.2016.07.059. Epub 2016 Aug 6. Review.

PMID:
27507699
12.

Antisense oligonucleotide therapy for neurodegenerative disease.

Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, Cleveland DW.

J Clin Invest. 2006 Aug;116(8):2290-6. Epub 2006 Jul 27.

13.

Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Kasai T, Tokuda T, Ishigami N, Sasayama H, Foulds P, Mitchell DJ, Mann DM, Allsop D, Nakagawa M.

Acta Neuropathol. 2009 Jan;117(1):55-62. doi: 10.1007/s00401-008-0456-1. Epub 2008 Nov 7.

PMID:
18989684
14.

ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations.

Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H.

Mol Genet Metab. 2012 Mar;105(3):472-8. doi: 10.1016/j.ymgme.2011.11.201. Epub 2011 Dec 10.

PMID:
22264771
15.

In vivo kinetic approach reveals slow SOD1 turnover in the CNS.

Crisp MJ, Mawuenyega KG, Patterson BW, Reddy NC, Chott R, Self WK, Weihl CC, Jockel-Balsarotti J, Varadhachary AS, Bucelli RC, Yarasheski KE, Bateman RJ, Miller TM.

J Clin Invest. 2015 Jul 1;125(7):2772-80. doi: 10.1172/JCI80705. Epub 2015 Jun 15.

16.

Clinical value of decreased superoxide dismutase 1 in patients with epilepsy.

Chen D, Lu Y, Yu W, Luo J, Xiao Z, Xiao F, Wang X.

Seizure. 2012 Sep;21(7):508-11. doi: 10.1016/j.seizure.2012.05.003. Epub 2012 May 29.

17.

Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models.

Kato S, Kato M, Abe Y, Matsumura T, Nishino T, Aoki M, Itoyama Y, Asayama K, Awaya A, Hirano A, Ohama E.

Acta Neuropathol. 2005 Aug;110(2):101-12. Epub 2005 Jun 28.

PMID:
15983830
18.

Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Zhang C, Zhou C, Teng JJ, Zhao RL, Song YQ, Zhang C.

Cytotherapy. 2009;11(3):299-306. doi: 10.1080/14653240902806986. Erratum in: Cytotherapy. 2009;11(6):807. Zheng, Chen [added].

PMID:
19333801
19.

Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease.

Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Kasai N, Brown RH Jr, Itoyama Y.

J Neurosci. 2001 Dec 1;21(23):9246-54.

20.

ALS with variable phenotypes in a six-generation family caused by leu144phe mutation in the SOD1 gene.

Masè G, Ros S, Gemma A, Bonfigli L, Carraro N, Cazzato G, Rolfo M, Zanconati F, Sepcic J, Jurjevic A, Pirulli D, Boniotto M, Zezlina S, Crovella S, Amoroso A.

J Neurol Sci. 2001 Oct 15;191(1-2):11-8.

PMID:
11676987

Supplemental Content

Support Center